HMP Global

Oncology Learning Network

Health EN ↓ 191 episodes

Podcast by HMP Global

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

HMP Global

Category

Health

Podcast website

soundcloud.com

Latest episode

Nov 4, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer 15.03.2022

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC 02.03.2022

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC by HMP Global

Dr Chi, MD, Discusses Phase 3 MAGNITUDE, SPARTAN, and TITAN Study Results 17.02.2022

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Dr Melani Shares Impressive Results of the ViPOR Trial for MCL 02.02.2022

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Dr Slavin Discusses Ways to Improve PRS by Reducing Ancestral Bias in BC 15.12.2021

Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias.

Dr Mascarenhas Discusses AVID200 for Patients With Myelofibrosis 15.12.2021

John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.

Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM 15.12.2021

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Dr Wildgust Discusses Racial Disparities in Treatment Patterns,Outcomes in MM 15.12.2021

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting.

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma 22.11.2021

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma by HMP Global

Dr Aggarwal Discusses Plasma-Based Next-Generation Sequencing for Patients with Nonsquamous NSCLC 17.11.2021

Charu Aggarwal, MD, Penn Medicine, Philadelphia, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.

Tapan Kadia, MD, Highlights Venetoclax Plus Chemotherapy for AML, MDS 11.11.2021

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Dr Elhassadi Highlights the Impact of a p53 Alteration in Patients With MCL 25.10.2021

Ezzat Elhassadi, MD, Consultant Hematologist, University Hospital, Waterford, Ireland, discusses the impact of a p53 alteration in patients with mantle cell lymphoma (MCL); these data were presented at the EHA2021 Virtual Congress.

Dr Morikawa Discusses Assessing Risk of Brain Metastasis in HER2+ Breast Cancer 05.10.2021

Aki Morikawa, MD, PhD, The University of Michigan, discusses assessing risk of brain metastasis in HER2+ breast cancer.

Talquetamab Well Tolerated in Relapsed/Refractory MM 08.06.2021

Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.

Improvements in the Treatment of Patients With MCL Over the Past Decade 07.06.2021

Peter Martin, MD, talks about the various treatment patterns and outcomes of US patients with MCL over the past 10 years, the findings of which were presented at the 2021 ASCO Annual Meeting.

Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers 07.06.2021

Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers by HMP Global

Holly Pederson, MD, Discusses Ancestrally Unbiased Polygenic Breast Cancer Risk Assessment 07.06.2021

Holly Pederson, MD, Cleveland Clinic, discusses siscusses ancestrally unbiased polygenic breast cancer risk assessment, presented at the 2021 ASCO Annual Meeting.

Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML 04.06.2021

Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.

Nirav Shah, MD, Discusses Dual-Targeted CAR T Cells for HL, CLL 07.05.2021

Dr Shah discusses his story on bispecific anti-CD20, anti-CD19 CAR T cells for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia.

ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer 23.04.2021

Nakia Spencer, Associate Scientist, MD Anderson Cancer Center, discusses the ongoing clinical trial of asparagine synthetase (ASNS) expression predicting response to the GLS1 inhibitor IPN60090 in ovarian cancer, through selective modulation of redox homeostasis, presented at the 2021 AACR Annual Meeting.

Dr Shitara Discusses Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer 17.02.2021

Dr Shitara Discusses Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer by HMP Global

Dr Saad Highlights Results Following the ACIS Study 16.02.2021

Fred Saad, MD, University of Montreal Hospital Center, highlights, "Results from ACIS, a Randomized, Placebo Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate Plus Prednisone Versus Abiraterone in Patients with Chemo-Naive Castration-Resistant Prostate Cancer."

Andres Cervantes, MD, PhD, Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer 18.01.2021

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and new advancements in treatment of HER2+ gastric cancer.

Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies 17.12.2020

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)."

Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC 16.12.2020

Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.

Listen to the Oncology Learning Network podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.